Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysis Todd Davis - CEO Paul Hadden - Senior Vice President of Investments and Business Development Tavo Espinoza - Chief Financial Officer Lauren Hay - Vice President of Strategic Planning and Investment Analytics Conference Call Participants Matt Hewitt - Craig-Hallum Joseph Pantginis - HC Wainwright Douglas Miehm ...

Financial Data and Key Metrics Changes - Ligand reported total revenue of $167 million for 2024, a 27% increase from $131.3 million in 2023 [25] - Royalty revenue grew by 28% to $108.8 million from $85 million in 2023, primarily driven by FilSpari and CarXiva [25] - Core adjusted EPS increased by over 40% to $5.74 per share [6][25] - Operating cash flow exceeded $100 million in 2024 [7] - GAAP net loss for 2024 was $4 million, compared to a net income of $53.8 million in 2023 [27] - Adjusted net income for 2024 was $156 million or $8.25 per diluted share, compared to $107.4 million or $6.09 per diluted share in 2023 [28] Business Line Data and Key Metrics Changes - Royalty revenue in Q4 2024 increased by 55% to $34.8 million from $22.5 million in Q4 2023 [28] - FilSpari sales totaled $132 million in 2024, generating approximately $12 million in royalty proceeds for Ligand [26] - Captisol sales were $30.9 million in 2024, up from $28.4 million in 2023 [26] Market Data and Key Metrics Changes - Recordati reported sales of Carceba at EUR 227 million in 2024, a 13% increase from 2023 [33] - Filspari's sales in Q4 2024 reached $50 million, a 40% increase compared to Q3 2024 [36] - Otuvare sales in Q4 were $36 million, significantly surpassing consensus estimates [37] Company Strategy and Development Direction - Ligand is focused on acquiring differentiated royalty assets and maintaining a low operating expense structure [6][12] - The company aims for a long-term royalty revenue growth rate of 20% CAGR from 2024 to 2029 [14] - Ligand's strategy includes investing in high-growth, low OpEx assets, with a strong emphasis on risk-reward opportunities [13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future prospects, citing a robust business development pipeline and strong financial position [15][44] - The company anticipates continued growth in royalty revenue, particularly from FilSpari and Otuvare [36][38] - Management highlighted the significant unmet need in the COPD market and the potential for Otuvare to capture a large share [85] Other Important Information - Ligand ended 2024 with $256 million in cash and investments, with access to a $125 million revolving credit facility [7][25] - The company has restructured its business model to focus on profitable and compounding growth, reducing cash operating expenses by over 50% [11] Q&A Session Summary Question: Is the recent investment into Castle Creek Ligand's first move into cell and gene therapies? - Yes, it is Ligand's first cell and gene therapy investment, and the company is open to more opportunities in this area [48] Question: What is the expected impact of the SQ Innovations, Lasix launch on Captisol sales? - Captisol will see some sales from SQ Innovations, but it will not be a major contributor [53] Question: How does the DeFi deal signal Ligand's ability to do more syndicated deals? - Ligand will syndicate deals when necessary, focusing on maintaining a diversified risk portfolio [56] Question: What is the expected financial impact of the termination letter to Kasi on Ligand? - There is no expected material impact for 2025, as the licensing agreement with Acrotech will continue [106] Question: How has the opportunity set changed since the last update? - There has been an uptick in the pipeline, with a disciplined approach to selecting high-value opportunities [110]

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.25 1 A reconciliation of forward-looking non-GAAP adjusted earnings per diluted share to the most directly comparable GAAP measure is not available without unreasonable effort, as certain items cannot be reasonably predicted because of thei ...

Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share1 of $6.00-$6.25 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2024, and provided an operating forecast and business updat ...

Capital will fund Castle Creek’s D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors invested $25 million in return for a high-single digit royalty on D-Fi JUPITER, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has closed a royalty financing agreement with Castle Creek Biosciences, Inc. to support the Phase 3 clinical study of D- ...

Group 1 - The biotech forum has seen significant discussions around profitable buy-write or covered call strategies on selected biotech stocks in recent months [1] - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has been highlighted due to its substantial share price increase in recent months, indicating a potential investment opportunity [2] - The Biotech Forum offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat for trade ideas and weekly market commentary [2] Group 2 - The article emphasizes the importance of community engagement for real-time trading ideas among seasoned biotech investors [1][2]

Core Insights - Ligand Pharmaceuticals (NASDAQ: LGND) has shown a modest increase of approximately 9.6% since the last article published in July 2024, where it was rated as a "Buy" [1] Company Performance - The company is recognized as a solid performer in the healthcare sector, with a focus on continuous learning from both investment successes and failures [1] Analyst Perspective - The author has a beneficial long position in Ligand shares, indicating confidence in the company's future performance [2] - The article reflects the author's personal opinions and experiences, emphasizing a commitment to sharing insights gained from years of investing and research [1][2]

Revenue and Income - Total revenue and other income increased by $18.9 million, or 58%, to $51.8 million in Q3 2024 compared to $32.9 million in Q3 2023[110] - Royalties increased by $7.8 million, or 33%, to $31.7 million in Q3 2024 compared to $23.9 million in Q3 2023, primarily due to income from QARZIBA and an increase in FILSPARI sales[110] - Contract revenue and other income surged by $13.5 million, or 3,623%, to $13.8 million in Q3 2024 compared to $0.4 million in Q3 2023, mainly due to a commercial milestone tied to Verona's Ohtuvayre[110] - Year-to-date total revenue and other income increased by $21.1 million, or 20%, to $124.3 million in YTD 2024 compared to $103.2 million in YTD 2023[111] - Year-to-date royalties increased by $11.5 million, or 18%, to $74.0 million in YTD 2024 compared to $62.5 million in YTD 2023, driven by QARZIBA and FILSPARI sales[111] - Revenue from intangible royalty assets for Q3 2024 was $26.6 million, up from $23.9 million in Q3 2023, reflecting increased partner product sales[112] - Kyprolis generated $11.6 million in royalty revenue in Q3 2024, with an effective royalty rate of 2.9% on estimated partner product sales of $405.4 million[112] - FILSPARI had a fixed royalty rate of 9%, contributing $3.2 million in royalty revenue in Q3 2024[112] - YTD 2024 estimated partner product sales for Kyprolis reached $1,213.7 million, up from $1,123.3 million in YTD 2023, representing an increase of 8.0%[114] Operating Costs and Expenses - Total operating costs and expenses increased by $47.3 million, or 52%, to $137.3 million in YTD 2024 compared to $90.0 million in YTD 2023[117] - Total operating costs and expenses for Q3 2024 were $48.7 million, a 53% increase from $31.9 million in Q3 2023[116] - General and administrative expenses rose to $53.0 million in YTD 2024, compared to $36.8 million in YTD 2023, an increase of 44.4%[118] - Research and development expenses were $17.0 million for YTD 2024, down from $19.0 million in YTD 2023, a decrease of 10.0%[118] - Financial royalty asset impairment was $26.5 million for YTD 2024, primarily due to Takeda's soticlestat missing its phase 3 clinical trial primary endpoint[118] - Cost of Captisol decreased by $1.0 million, or 30%, to $2.4 million in Q3 2024 compared to $3.5 million in Q3 2023[116] Financial Performance - Q3 2024 net loss before income taxes was $(6,339) thousand, an improvement of $5,805 thousand compared to Q3 2023's $(12,144) thousand[124] - Year-to-date (YTD) 2024 net cash provided by operating activities was $68,576 thousand, up from $41,512 thousand in YTD 2023[128] - YTD 2024 cash used in investing activities totaled $(105,041) thousand, significantly higher than $(1,398) thousand in YTD 2023[128] - The company generated $76,753 thousand from financing activities in YTD 2024, compared to $(65,262) thousand in YTD 2023[128] Cash and Investments - As of September 30, 2024, cash, cash equivalents, and short-term investments totaled $219.6 million, an increase of $49.3 million from the end of the previous year[125] - The company has a stock repurchase program authorizing up to $50 million of common stock, remaining available as of September 30, 2024[126] - The Revolving Credit Facility was increased from $75 million to $125 million on July 8, 2024, with $124.4 million available for borrowing as of September 30, 2024[126] - Gain from short-term investments was $98.9 million in YTD 2024, compared to $30.3 million in YTD 2023, an increase of 226.8%[123] Tax and Discontinued Operations - The effective tax rate for Q3 2024 was (13.1)%, compared to 15.4% in Q3 2023, reflecting changes in non-deductible items and foreign operations[124] - Net loss from discontinued operations was zero for both Q3 2024 and Q3 2023, with YTD 2024 also showing no loss compared to $(1.7) million in YTD 2023[125] Future Plans - The company plans to host an investor and analyst day on December 10, 2024, to review business progress and introduce 2025 guidance[105] Derivatives and Liabilities - The fair value adjustment to partner program derivatives was $7.8 million for Q3 2024, primarily due to certain Agenus partners discontinuing development of their partnered programs[116] - The company had $4.0 million in fair value of contingent consideration liabilities associated with prior acquisitions as of September 30, 2024[126]

Financial Data and Key Metrics Changes - Total revenues for Q3 2024 reached $51.8 million, representing a 58% increase over Q3 2023 [42] - Royalty revenue increased by 33% to $31.7 million, up from $23.9 million in the same period last year [42] - Adjusted earnings per share (EPS) was $1.84, an 80% increase over Q3 2023 [48] - The company ended the quarter with nearly $350 million in available investable capital [42] Business Line Data and Key Metrics Changes - Key drivers of royalty revenue growth included the addition of QARZIBA and strong performance from Amgen's Kyprolis and Travere's FILSPARI [43] - Amgen reported $378 million in Kyprolis sales, marking an 8% year-over-year increase [43] - Travere reported $35.6 million in FILSPARI sales, with a 31% sequential growth [44] Market Data and Key Metrics Changes - The FDA granted full approval for Travere's FILSPARI, expanding its indication to include patients with IgAN at risk for disease progression [24] - CAPVAXIVE was launched by Merck during Q3 2024, with the CDC recommending it for adults aged 50 and older, expanding its potential market [32][33] - Ohtuvayre achieved quarterly net sales of $5.6 million, with October sales exceeding the entire third quarter [45] Company Strategy and Development Direction - The company aims to acquire high-value royalty-generating assets and has access to over $300 million in capital for this strategy [8] - Ligand's strategic differentiation focuses on generating profitable, diversified, compounding growth through late-stage development assets [16] - The company is optimistic about its long-term royalty revenue growth, projecting a compound annual growth rate (CAGR) above 20% [52] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the robust pipeline and high demand for capital in the pharmaceutical industry, which is generally uncorrelated with market volatility [55][56] - The company is optimistic about the future prospects, with a strong focus on high unmet clinical needs driving investment decisions [86] - Management highlighted the potential of FILSPARI as a foundational treatment for IgAN and its expansion into FSGS, a significant area of unmet need [68] Other Important Information - The company raised its 2024 total revenue forecast to a range of $100 million to $165 million, with adjusted EPS expected between $5.50 and $5.70 [50] - Ligand is currently reviewing over 20 investment opportunities representing more than $800 million of investment potential [22] Q&A Session Summary Question: What does the pipeline look like and how do election results impact investment? - Management stated the pipeline remains robust and that capital demand is high regardless of election results, emphasizing the non-correlated nature of royalties with market volatility [55][56] Question: Can you provide details on the 25 potential investments being considered? - About half of the opportunities involve project finance, creating synthetic royalties, while the rest includes M&A and passive royalties [60][61] Question: What is the competitive environment for Travere's FILSPARI? - Management believes FILSPARI will be foundational in treating IgAN and is optimistic about its potential in FSGS, where there are currently no approved treatments [66][68] Question: Is Ligand rightsized in terms of employee base and capital access? - Management indicated that the current team is well-structured and that high operating leverage allows for growth without significantly increasing headcount [71] Question: What is the status of the buyback program? - The buyback program is in place for corporate hygiene, with no immediate plans to utilize it unless significant market dislocations occur [72] Question: How should Captisol's revenue mix be viewed going forward? - The revenue mix remains consistent, with 80% coming from 20% of the customer base, and management is encouraged by the activity from smaller research customers [73]

Revenue Growth - Total revenue and other income increased by $15.2 million, or 58%, to $41.5 million in Q2 2024 compared to $26.4 million in Q2 2023[100] - Revenue from intangible royalty assets increased by $2.2 million, or 11%, to $22.6 million in Q2 2024, primarily due to increases in FILSPARI sales[100] - Captisol sales increased by $2.3 million, or 44%, to $7.5 million in Q2 2024, primarily due to the timing of customer orders[100] - Contract revenue and other income increased by $10.7 million, or 5,125%, to $10.9 million in Q2 2024, primarily due to milestones tied to FDA and EMA approvals[100] - Total revenue and other income increased by $2.2 million, or 3%, to $72.5 million in YTD 2024 compared to $70.3 million in YTD 2023[101] - Revenue from intangible royalty assets increased by $3.4 million, or 9%, to $41.0 million in YTD 2024 compared to $37.6 million in YTD 2023, primarily due to increases in FILSPARI sales[101] Expenses and Impairments - Total operating costs and expenses increased by $30.5 million, or 52%, to $88.6 million in YTD 2024 compared to $58.1 million in YTD 2023, primarily due to a $26.5 million financial royalty asset impairment[108] - Research and development expense was $11.3 million for YTD 2024, compared with $13.5 million for YTD 2023, reflecting a decrease primarily due to the sale of the Pelican business[108] - Financial royalty asset impairment was $26.5 million for YTD 2024, compared to zero for YTD 2023, due to Takeda's Soticlestat missing its phase 3 clinical trial endpoint[108] - General and administrative expense was $28.6 million for YTD 2024, compared to $22.1 million for YTD 2023, primarily due to increased stock compensation for new hires[108] Non-Operating Income and Losses - Total non-operating income and expenses, net, was $(46.3) million in Q2 2024 compared to $5.2 million in Q2 2023, reflecting a significant loss from short-term investments[109] - The loss from short-term investments was $14.3 million in Q2 2024, compared to a gain of $4.0 million in Q2 2023, driven by changes in the fair value of ownership in Viking common stock[110] - Other non-operating expenses increased by $35.4 million in YTD 2024 compared to YTD 2023, primarily due to revaluation of Primrose investments[113] Cash and Investments - Cash, cash equivalents, and short-term investments totaled $226.9 million as of June 30, 2024, an increase of $56.6 million from the end of the previous year[116] - Cash used in investing activities was $(58.5) million in YTD 2024, compared to $18.1 million generated in YTD 2023[117] - Gain from short-term investments increased to $96.5 million in YTD 2024 from $43.5 million in YTD 2023, with an unrealized gain on Viking shares of $21.8 million compared to $5.1 million in the prior year[113] Acquisitions and Mergers - The company announced a $100 million acquisition of APEIRON Biologics, which holds royalty rights to QARZIBA for treating high-risk neuroblastoma[94] - The company anticipates owning approximately 2% of the combined company following the close of the Palvella and Pieris merger[96] Royalties and Milestones - Ligand earned a $5.8 million milestone payment upon FDA approval of Ohtuvayre and will earn an additional $13.8 million upon its commercial launch[97] - Ligand is entitled to a royalty of approximately 3% on future worldwide net sales of Ohtuvayre[97] - Ligand will receive a royalty of 8-9.8% on worldwide commercial sales of QTORIN rapamycin[96] - Effective royalty rates for key products such as Kyprolis and Evomela remained stable at 1.9% and 20.0%, respectively, while Filspari maintained a fixed royalty rate of 9%[102] Financing and Credit Facilities - The revolving credit facility with Citibank was amended to increase the aggregate amount from $75 million to $125 million[94] - The company entered into a $75 million Revolving Credit Facility, which was increased to $125 million on July 8, 2024[116] Taxation - The effective tax rate for Q2 2024 was 20.6%, down from 27.8% in Q2 2023, while the effective tax rate for YTD 2024 was 28.8% compared to 21.8% in YTD 2023[114] Net Cash from Operations - Net cash provided by operating activities was $32.0 million in YTD 2024, down from $33.9 million in YTD 2023[117] Discontinued Operations - Net loss from discontinued operations was zero for both Q2 2024 and Q2 2023, while YTD 2023 recorded a loss of $1.7 million[115]